Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IBI 363

X
Drug Profile

IBI 363

Alternative Names: IBI-363

Latest Information Update: 04 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Class Antibodies; Antineoplastics; Cytokines; Immunotherapies; Interleukins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin-2 expression stimulants; Interleukin-2 replacements; Programmed cell death-1 ligand-1 inhibitors; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 28 Feb 2024 Innovent Biologics plans a phase II trial for Solid tumors (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT06281678)
  • 19 Oct 2023 Phase-I/II clinical trials in Malignant melanoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in China (Parenteral) (NCT06081920)
  • 13 Oct 2023 Innovent Biologics plans a phase Ib/II trial for Malignant melanoma (Late-stage disease; Second-line therapy or greater; Metastatic disease; Inoperable/Unresectable)in China (Parenteral) (NCT06081920)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top